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1 INTRODUCTION 
1.1 Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third 
leading cause of cancer-related death. It accounts for 695,900 deaths per year and its 
incidence rate is increasing. Chronic liver injuries and cirrhosis caused by hepatitis B or C 
virus infection, alcoholic liver disease and inherited metabolic diseases contribute most 
frequently to the development of HCC.1, 2 Liver transplantation and surgical resection are 
the major choices of curative treatment for patients with early-stage HCC. Radiofrequency 
ablation (RFA), transarterial chemoembolization (TACE) and radioembolization are 
additional therapeutic options for intermediate-stage HCC. Nevertheless in most cases 
HCC is diagnosed at an advanced stage when these approaches are no longer feasible.3-5 
The only approved systemic therapeutic option for this stage is oral sorafenib treatment.6 
However, the prognosis for these patients is still poor, because the response to sorafenib 
remains low and the median overall survival is only extended by 2.8 months.7 Therefore, 
the development of novel targeted therapies for HCC is of paramount clinical importance. 
 
1.2 Cyclin dependent kinase 5 
Cyclin dependent kinase 5 (Cdk5) was discovered in the early 1990s8 and shares 60% 
structural identity with Cdk1 and Cdk2. Nevertheless Cdk5 is a unique member of the Cdk 
family with respect to its function and regulation. It is not a classical mediator of cell cycle 
progression, but it regulates the cytoarchitecture in the central nervous system (CNS) and 
thereby is important for neuronal development, function and disease. A huge number of 
studies investigated Cdk5 function in the CNS, but during recent years Cdk5 turned out 
not to be neuron specific. Some reports also indicate a role of Cdk5 in endothelial, 
epithelial, immune, and cancer cells.9, 10  
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1.2.1 Regulation of Cdk5 
Almost the complete knowledge about Cdk5 regulation up to now is gained in neuronal 
cells. In neurons, Cdk5 activity is mainly regulated by association with one of the two 
obligate Cdk5-specific activator proteins, p35 or p39. Both share about 57% amino acid 
homology.9, 11-13 Interestingly, p35 can mask the absence of p39, whereas p39 can 
compensate only some function of p35.9, 14  
These two activator proteins themselves are regulated by transcription and ubiquitin-
mediated degradation. In addition to the activation, p35/p39 determined the subcellular 
distribution of Cdk5, as a myristoylation motif targets them to cell membranes and cell 
periphery.11, 15 The activity of Cdk5 is reported to be also increased by phosphorylation at 
Tyr15. The responsible kinases are c-Abelson (c-Abl)16 and Fyn17 (Figure 1). However, the 
influence of this phosphorylation on Cdk5 activity is controversially discussed as 
Kobayashi et al. recently showed in neuronal cells that it has no activating effect on 
Cdk5.18 
 
 
Figure 1 Regulation of Cdk5. Cdk5 is activated by association with p35 or p39 and via 
phosphorylation at Tyr15 by e.g. c-Abl and Fyn. P35 and p39 are myristoylated and thus recruit 
Cdk5 by interaction to the cell membrane. Moreover, these activator proteins are regulated by 
ubiquitin-mediated degradation. 
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1.2.2
Although Cdk5 is ubiquitously expressed, Cdk5 function is most prominent in cells of 
neuronal origin. 
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1.2.3 Function of Cdk5 in cancer 
Over the past decade, the compendium of extraneuronal functions of Cdk5 has 
expanded.10, 28, 29 Some publications suggested an association between Cdk5 and human 
cancer progression. Cdk5 has been implicated in the regulation of prostate cancer cell 
motility, proliferation of medullary thyroid carcinoma cells, and control of apoptosis in 
leukemia and astrocytoma cells.30-36 In pancreatic cancer Cdk5 activity is important for 
cancer formation, progression and systemic metastasis.37 Nevertheless, Cdk5‘s function 
in cancer is still insufficiently studied and nothing is known about its role in HCC. 
 
1.2.4 Pharmaceutical inhibition of Cdk5 
The first more or less specific Cdk5 inhibitors were olomoucine38 and roscovitine 
(Seliciclib, CYC202).39 Both compounds belong to the family of 2, 6, 9-trisubstituted 
purines (Figure 3) and interact with the ATP-binding pocket of the kinases. As this 
catalytic site is quite conserved throughout the Cdk family, it is hard to design selective 
inhibitors for one specific Cdk.40, 41 Various targets of these agents have been identified. 
Olomoucine inhibits mainly Cdk1, Cdk2, Cdk5 and ERK1,38, 41 whereas roscovitine targets 
Cdk1, Cdk2, Cdk5, Cdk7, Cdk9, ERK1/2 and pyridoxal kinase.39, 40 This pretended 
disadvantage can be turned into an advantage in context of clinical use, as at least the 
tumor progression is a multi-factorial disease and multi-target therapeutics might be 
favored.42, 43 
 
A 
 
B 
 
Figure 3 Chemical structure of (A) olomoucine and (B) (R)-roscovitine. 
In context of neurodegenerative diseases some companies are also developing new Cdk5 
inhibitors with increased specificity.44, 45 
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1.3 Aim of the study 
Development of novel efficient therapy for HCC is of paramount clinical importance, as the 
prognosis for patients with advanced HCC is still very poor. Few reports show an 
involvement of Cdk5 in tumor progression of e.g. prostate and pancreatic cancer. 
However, the knowledge on Cdk5‘s function in cancer is still incomplete and its role in 
HCC is completely unknown up to now. 
 
 
Therefore the aim of this study was to investigate the function of Cdk5 in HCC 
progression, focusing on the major hallmarks: tumor cell motility and tumor cell growth. In 
addition, the underlying mechanism of Cdk5’s influence in HCC cells was examined. 
Furthermore, novel therapeutic strategies for HCC should be evaluated by combining 
Cdk5 inhibition with established chemotherapeutics.  
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Compounds 
(R)-Roscovitine, aphidicolin, doxorubicin, etoposide and nocodazol were obtained from 
Sigma-Aldrich. Sn38 was obtained from Tocris Bioscience. ABT-888 and sorafenib were 
obtained from Enzo Life Sciences. 
 
2.1.2 Reagents and technical equipment 
Table 1   Biochemicals, inhibitors, dyes and cell culture reagents 
Reagent Producer 
32P-γ-ATP Hartmann Analytic, Braunschweig, Germany 
AEC substrate Vector Laboratories, Burlingame, CA, USA 
ApopTag® Plus Fluorescein In Situ 
Apoptosis Detection Kit (S7111) 
Chemicon International, Atlanta, GA, USA 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Bradford ReagentTM Bio-Rad, Munich, Germany 
Collagen G Biochrom AG, Berlin, Germany 
Complete® Roche diagnostics, Penzberg, Germany 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
PAA Laboratories, Pasching, Austria 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
DharmaFECT Transfection reagent Thermo Scientific, Waltham, MA, USA 
FCS Biochrom AG, Berlin, Germany 
FluorSaveTM Reagent Merck, Darmstadt, Germany 
Mayer’s Hematoxylin Solution Sigma-Aldrich, Taufkirchen, Germany 
Histone H1 (Type III from calf thymus) Sigma-Aldrich, Taufkirchen, Germany 
Hoechst 33342 Sigma-Aldrich, Taufkirchen, Germany 
ibiTreat µ-slides ibidi GmbH, Munich, Germany 
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Reagent Producer 
Matrigel® BD Biosciences, Bedford, MA, USA 
Nitrocellulose membrane Hybond-ECLTM, Amersham Bioscience, 
Freiburg, Germany 
NucleofectorTM Kit T Lonza, Basel, Switzerland 
Sodium fluoride (NaF) Merck, Darmstadt, Germany 
Sodium orthovanadate (Na3VO4) ICN Biomedicals, Aurora, Ohio, USA 
Page RulerTM Prestained Protein 
Ladder 
Fermentas, St. Leon-Rot, Germany 
Penicillin PAA Laboratories, Pasching, Austria 
Phenylmethylsulfonylfluoride (PMSF)  Sigma Aldrich, Munich, Germany 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
Protein G agarose beads Sigma-Aldrich, Taufkirchen, Germany 
RPMI 1640 PAA Laboratories, Pasching, Austria 
Streptomycin PAA Laboratories, Pasching, Austria 
Triton X-100 Merck, Darmstadt, Germany 
Transwell Permeable Supports (8 µm 
pore polycarbonate inserts) 
Corning Incorporated, New York, NY, USA 
Vectastain® Universal Elite ABC Kit Vector Laboratories, Burlingame, CA, USA 
X-ray film (Super RX) Fuji, Düsseldorf, Germany 
 
Table 2   Technical equipment 
Name Producer 
Axioskop microscope Zeiss, Jena, Germany 
Axiovert 25 / 200 microscope Zeiss, Jena, Germany 
Canon 450D camera Canon, Krefeld, Germany 
Canon DS 126181 camera Canon, Krefeld, Germany 
Curix 60 Agfa, Cologne, Germany 
FACSCalibur Becton Dickinson, 
Heidelberg, Germany 
Mikro 22R centrifuge Hettich, Tuttlingen, Germany 
NucleofectorTMII Amaxa, Cologne, Germany 
Olympus DP25 camera Olympus, Hamburg, Germany 
Olympus BX41 microscope Olympus, Hamburg, Germany 
  
2  MATERIALS AND METHODS 18 
  
 
 
Name Producer 
Odyssey 2.1 LI-COR Biosciences, 
Lincoln, NE, USA 
SpectraFluor PlusTM Tecan, Crailsheim, Germany 
Vi-Cell™ XR Beckman Coulter, Fullerton, CA, USA 
xCELLigence System Roche Diagnostics, Mannheim, Germany 
Zeiss LSM 510 Meta confocal laser 
scanning microscope 
Zeiss, Jena, Germany 
  
2.2 Cell culture  
2.2.1 Solutions and reagents 
The following solutions and reagents were used for the cultivation of HCC cells. 
Table 3   Solutions and reagents for cell culture 
PBS (pH 7.4)  PBS+Ca2+/Mg2+ (pH 7.4) 
NaCl  132.2 mM  NaCl  137 mM 
Na2HPO4  10.4 mM  KCl 2.68 mM 
KH2PO4  3.2 mM  Na2HPO4  8.10 mM 
H2O   KH2PO4  1.47 mM 
   MgCl2  0.25 mM 
   H2O   
 
Growth medium  Freezing medium 
DMEM 500 ml  DMEM 70% 
FCSgold 
(not heat-inactivated) 
50 ml  FCSgold 
(not heat-inactivated) 
20% 
   DMSO 10% 
 
Trypsin/EDTA (T/E)  Collagen G 
Trypsin  0.05%  Collagen G 0.001% 
EDTA  0.20%  PBS  
PBS      
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2.2.2 Cell lines 
HUH7 and HepG2 cells were obtained from Japanese Collection of Research 
Bioresources (JCRB) and German Research Centre of Biological Material (DSMZ) 
(ACC180), respectively. All cells were grown in DMEM supplemented with 10% fetal calf 
serum (FCS). Cells were cultured under constant humidity at 37°C and with 5% CO2 in an 
incubator. All culture flasks, multiwell-plates and dishes were first coated with collagen G 
(0.001% in PBS) before seeding the cells. 
 
2.2.3 Passaging 
After reaching confluency, cells were either sub-cultured 1:2 - 1:10 in 75 cm2 culture flasks 
or seeded either in multiwell-plates or dishes for experiments. For passaging, medium 
was removed and cells were washed with PBS before incubation with trypsin/ethylene 
diamine tetraacetic acid (EDTA) (T/E) for 1-2 min at 37°C. Thereafter, cells were gradually 
detached and the digestion was stopped using growth medium. After adjusting the cell 
concentration in growth medium and cells were plated. 
 
2.2.4 Freezing and thawing 
For freezing, confluent cells from a 150 cm2 flask were trypsinized, centrifuged 
(1,000 rpm, 5 min, 20°C) and resuspended in ice-cold freezing medium. 1.5 ml aliquots 
were frozen in cryovials. After storage at -80°C for 24 h, aliquots were moved to liquid 
nitrogen for long term storage. 
For thawing, a cryovial was warmed to 37°C and the content was immediately dissolved in 
prewarmed growth medium. In order to remove DMSO, cells were centrifuged, 
resuspended in fresh growth medium and plated in a 25 cm2 culture flask. The next day 
cells were washed carefully and after reaching about 80% confluency transferred to a 
75 cm2 culture flask. 
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2.3 Transfection experiments 
2.3.1 Cdk5 and p27Kip1 siRNA 
Cells were transfected for 24 h to 7 d by lipofection using DharmaFECT Transfection 
reagent or by electroporation using NucleofectorTMII according to the manufacturer’s 
protocol. For Cdk5 silencing two different ON-TARGETplus Cdk5 siRNA were used in an 
equal mixture (J-003239-09 and J-003239-10; Thermo Scientific). Furthermore, ON-
TARGETplus CDKN1B siRNA SMARTpool (L-003472-00; Thermo Scientific) was used for 
p27Kip1 silencing and ON-TARGETplus Non-targeting (nt) siRNA (D-001810-01; Thermo 
Scientific) served as transfection control. Silencing efficiency was examined by Western 
blot analysis. 
 
2.3.2 Cdk5 shRNA 
For the lentiviral transduction of HUH7 cells with Cdk5 shRNA and nt shRNA Cdk5 
MISSION® shRNA Lentiviral Transduction Particles (Vector: pLKO.1-puro; SHCLNV-
NM_004935; Clone ID: (1) TRCN0000021465, (2) TRCN0000021466, (3) 
TRCN0000021467, (4) TRCN0000194974, (5) TRCN0000195513; Sigma-Aldrich) and 
MISSION® pLKO.1-puro Non-Mammalian shRNA Control Transduction Particles 
(SHC002V; Sigma-Aldrich) as a control were used according to the manufacturer’s 
protocol. HUH7 cells were transduced with a multiplicity of infection (MOI) of one. 
Successfully transduced cells were selected by adding 2 µg/mL puromycin to the medium. 
After selection, the concentration of puromycin was reduced to 1 µg/mL for subsequent 
cultivation of the cells. By this the stable transfection of HUH7 cells with Cdk5 or nt shRNA 
could be ensured. Cdk5 knockdown of the different shRNA clones was examined by 
Western blot analysis and most efficient clone number 1 and 4 were used for further 
experiments. 
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2.4 Western blot analysis 
Cells were washed once with ice-cold PBS, lysis buffer was added and cells were frozen 
at -80°C. Afterwards, cells were scraped off and debris was removed by centrifugation 
(14,000 rpm, 10 min, 4°C). In order to employ equal amounts of protein in all samples for 
Western blot analysis, protein concentrations were determined using the Bradford assay. 
After measurement, protein concentration was adjusted by adding SDS sample buffer and 
samples were heated at 95°C for 5 min. Proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membranes by electro tank blotting. The membrane was 
blocked in 5% non-fat dry milk powder (Blotto) for 2h. Antibody incubation was done 
overnight at 4°C. Secondary antibodies were HRP-coupled or conjugated with an IR-
fluorescent Reagent. Chemiluminescence was detected with ECL substrate and exposure 
to X-ray films or fluorescence was detected with LI-COR Biosciences Odyssey®. 
 
 
Table 4   Solutions and reagents for Western blot analysis 
Lysis buffer   5x SDS sample buffer  
Tris/HCl 50 mM  Tris/HCl pH 6.8 3.125 M 
NaCl 150 mM  Glycerol 50% 
Nonidet NP-40 1%  SDS 5% 
Sodium deoxycholate 0.25%  DTT 2% 
SDS 0.10%  Pryonin Y 0.025% 
activated Na2VO4 300 µM  H2O  
NaF 1 mM    
β-glycerophosphate 3 mM    
pyrophosphate 10 mM    
H2O     
add before use:     
Complete® EDTAfree 4 mM    
PMSF 1 mM    
H2O2 600 µM    
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Separation gel 7.5%/10%/12%/15%  Stacking gel   
RotiphoreseTM Gel 30 25%/33%/ 
40%/50% 
 RotiphoreseTM Gel 30 17% 
Tris (pH 8.8) 375 mM  Tris (pH 6.8) 125 mM 
SDS 0.1%  SDS 0.1% 
TEMED 0.1%  TEMED 0.2% 
APS 0.05%  APS 0.1% 
H2O   H2O  
 
Electrophoresis buffer  Tank buffer  
Tris 4.9 mM  Tris base 48 mM 
Glycine 38 mM  Glycine 39 mM 
SDS 0.1%  Methanol 20% 
H2O   H2O  
 
Table 5   Primary antibodies 
Antigen Product no. Provider Dilution In 
actin MAB1501 Millipore 1:1,000 Blotto 1% 
Akt #9272 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
p-Akt (Ser473) #9271 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
p-ATM (Ser794) ab119799 abcam 1:1,000 BSA 5% 
p-ATM (Ser1981) #5883 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
p-ATR (Ser428) #2853 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
p-BRCA1 (Ser1524) #9009 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
p-cdc2 (Tyr15) #9111 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
Cdk5 AHZ0492 Invitrogen 1:1,000 Blotto 1% 
p-Cdk5 (Tyr15) EP762RY Epitomics 1:1,000 BSA 5% 
p-Chk1 (Ser345) #2348 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
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Antigen Product no. Provider Dilution In 
p-Chk2 (Thr68) #2661 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
CREB #9104 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
p-H2A.X (Ser139) #2577 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
p27Kip1 610241 
BD Transduction 
Laboratories 
1:1,000 Blotto 1% 
p35 sc-820 
Santa Cruz 
Biotechnology 
1:500 Blotto 1% 
β-tubulin #2146 
Cell Signaling 
Technology 
1:1,000 BSA 5% 
 
Table 6   Secondary antibodies 
Antibody Product no. Provider Dilution in 
Goat anti-mouse IgG1: 
HRP 
BZL07046 Biozol 1:1,000 Blotto 1% 
Goat anti-rabbit: HRP 
(H + L) 
111-035-144 Dianova 1:1,000 Blotto 1% 
Alexa Fluor® 680 Goat 
anti-mouse IgG (H + L) 
A - 21057 Molecular Probes 1:10,000 Blotto 1% 
IRDye™ 800CW Goat 
anti-rabbit IgG (H + L) 
926-32211 
LI-COR 
Biosciences 
1:10,000 Blotto 1% 
 
2.5 Nuclear/cytoplasmic fractionation 
Cells were washed once with ice-cold PBS, before additionally PBS is added. Afterwards 
cells were scraped off carefully, centrifuged (1,500 rpm, 10 min, 4°C) and the cell pellet 
was resuspended in nuclear extraction buffer A. After incubation on ice for 15 min, 
Nonidet P-40 (0.625%) was added, followed by vigorous vortexing. Probes were 
centrifuged (12,000 rpm, 1 min, 4°C) and supernatants as cytoplasmic fraction was 
removed. The pellet was incubated for 20 min at 4°C in nuclear extraction buffer B. After 
centrifugation (12,000 rpm, 5 min, 4°C) the supernatant as nuclear fraction was collected. 
In all fractions protein concentration was determined and adjusted by adding lysis buffer. 
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Afterwards the samples were either mixed with 5x SDS sample buffer for Western Blot 
analysis or were further used for immunoprecipitation and kinase activity assay. 
 
Table 7   Nuclear extraction buffer A and B 
Nuclear extraction buffer A  Nuclear extraction buffer B 
HEPES pH 7.9 10 mM  HEPES pH 7.9 20 mM 
KCl 10 mM  NaCl 0.4 mM 
EDTA 0.1 mM  EDTA 0.1 mM 
EGTA 0.1 mM  EGTA 0.1 mM 
DTT 1 mM  DTT 1 mM 
PMSF 0.5 mM  PMSF 0.5 mM 
Complete® EDTAfree 1 mM  Complete® EDTAfree 1 mM 
H2O   Glycerol 25% 
   H2O  
 
2.6 Immunoprecipitation 
Cells were harvested with IP lysis buffer (Table 8), scraped off and kept on ice for 30 min. 
Afterwards samples were centrifuged (14,000 rpm, 10 min, 4°C) and protein 
concentrations were determined in the supernatants. Cell lysates were incubated with 
2 µg antibody (Cdk5; sc-173, Santa Cruz Biotechnology) per 500 µg protein amount over 
night at 4°C. Thereafter, 25 µL packed Protein G Agarose beads with IP lysis buffer were 
added to each sample. After 3 h of incubation at 4°C, the beads were spun down and 
washed three times with lysis buffer. 
 
2.7 Kinase activity assay 
Beads from Cdk5 immunoprecipitation were resuspended in 50 µL kinase buffer. In 
addition, 2 µM ATP, 10 µCi 32P-γ-ATP and 0.05 µg/µL histone H1 (Type III from calf 
thymus) as a substrate were added to each sample and the enzyme reaction was carried 
out at 30°C for 20 min. For termination samples were mixed with 5x SDS sample buffer 
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and boiled for 5 min at 95°C. Aliquots of each sample were loaded onto a 12% SDS 
PAGE gel and electrophoresis was run. For autoradiography, an X-ray film was placed on 
the gel for 4 to 48 h at -80°C. 
 
Table 8   IP lysis buffer and kinase buffer 
IP lysis buffer  Kinase buffer 
Tris/HCl pH 7.5 50 mM  HEPES pH 7.0 
NaCl 250 mM  MgCl2 10 mM 
EDTA pH 8.0 1 mM  DTT 1 mM 
NaF 10 mM  NaF 1 mM 
SIGMAFAST™  1x  Na3VO4 1 mM 
Protease Inhibitor   PMSF 1 mM 
H2O   β-glycerophosphate 3 mM 
   Complete® EDTAfree 4 mM 
   H2O  
 
2.8 Human HCC microarrays 
Tissue microarray (TMA) containing human HCC samples as well as matched 
surrounding non-tumor tissue was kindly provided by Dr. E. De Toni (Department of 
Medicine II, University Hospital Großhadern, University of Munich, Germany).46 The 
included HCC patients had been treated with liver transplantation or partial hepatectomy 
at the University Clinic Munich Großhadern between 1985 and 2008.  
 
2.9 Immunohistochemistry 
2.9.1 Cdk5 and Ki-67 
5 µm sections of the TMA or tumor tissue from the HUH7 xenografts were used for 
immunohistochemical staining. The slides were deparaffinized in xylene (15 min) and 
rehydrated through descending concentrations of ethanol (20 min in 100% and 20 min in 
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95%). For antigen retrieval sections were boiled in sodium citrate buffer (10 mM sodium 
citrate, 0.05% Tween 20, pH 6.0) for 20 min. Endogenous peroxidase was blocked by 
incubation in 7.5% hydrogen peroxide for 10 min. Between the different steps the slides 
were always washed two times with PBS. Cdk5 antibody (ab40773; abcam) or Ki-67 
antibody (ab15580; abcam), diluted 1:100 in PBS, was applied as primary antibody for 1 h 
at room temperature. For antibody detection Vectastain® Universal Elite ABC Kit was 
taken according to the manual and AEC was used as a chromogen. Slides were 
counterstained with hematoxylin for 1 min and washed with distillated water. Finally, 
stained sections were embedded in FluorSaveTM Reagent mounting medium and covered 
with glass coverslips. Images were obtained with an Olympus BX41 microscope and an 
Olympus DP25 camera. 
 
2.9.2 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
Apoptotic cells in 5 µm sections from tumors derived from HUH7 xenografts were 
visualized using the ApopTag® Plus Fluorescein In Situ Apoptosis Detection Kit according 
to the manual. Cell nuclei were counterstained with 5 µg/mL Hoechst 33342 in PBS 
containing 1% BSA for 60 min. Stained sections were mounted with FluorSaveTM Reagent 
mounting medium. Images were obtained with a Zeiss LSM 510 Meta confocal laser 
scanning microscope. 
 
2.10 Immunostaining 
HCC cells were seeded in 8-well ibiTreat µ-slides. Afterwards, cells were washed once 
with ice-cold PBS+Ca2+/Mg2+ and fixed in 4% formaldehyde for 15 min, following one 
washing step with PBS. For permeabilization 0.2% Triton X-100 in PBS was applied for 
2 min. After washing with PBS, unspecific binding was blocked by incubation with 0.2% 
BSA in PBS for 20 min. Cells were incubated with the primary antibody against Cdk5 
(AHZ0492; Invitrogen), p27Kip1 (610241; BD Transduction Laboratories), Ki-67 (ab15580, 
abcam) and p-H2A.X (#2577; Cell Signaling Technology), diluted 1:100 in PBS containing 
0.2% BSA, for 1 h. Afterwards, cells were washed with PBS and incubated with Alexa 
Fluor® 488 or 546-conjugated secondary antibody (Invitrogen), diluted 1:400, together with 
5 µg/mL Hoechst 33342 in PBS containing 0.2% BSA for 30 min. After washing again with 
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PBS, stained cells were covered with FluorSaveTM Reagent mounting medium and glass 
coverslips. Images were obtained with a Zeiss LSM 510 Meta confocal laser scanning 
microscope. 
 
2.11 Proliferation assays 
2.11.1 Crystal violet staining 
HCC cells were seeded into 96-well plates. After 24 h incubation, cells in a reference plate 
were stained with crystal violet, serving as initial cell number. The cells in the remaining 
plates were either left untreated or stimulated with increasing concentrations of 
roscovitine. Upon an incubation period of 72 h, the medium was removed and cells were 
stained with 100 µL crystal violet solution for 10 min at room temperature. After washing 
with distilled water, the bound dye was solubilized by adding 100 µL of dissolving buffer. 
The absorbance was measured at 550 nm in a plate-reading photometer. 
Table 9   Crystal violet solution and dissolving buffer 
Crystal violet solution  Dissolving buffer 
Crystal violet 0.5%  Trisodium citrate 50 mM 
Methanol 20%  Ethanol 50% 
H2O     
 
2.11.2 Impedance measurement 
Proliferation of HCC cells with stable Cdk5 knockdown was determined using the 
xCELLigence System from Roche Diagnostics. HUH7 cells were seeded at a density of 
2,000 cells per 100 µL in equilibrated E-plates. After synchronizing the cells by treatment 
with 10 µM aphidicolin for 24 h, cells were either left untreated or treated with different 
substances as indicated for 72 h. The cell index, which is proportional to the cell number, 
was measured every hour and normalized to the value at the time of aphidicolin release. 
In the end the doubling time was evaluated by the xCELLigence software. 
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2.12 Colony formation assay 
The colony formation assay is an in vitro long term cell survival assay to determine the 
effectiveness of cytotoxic agents based on the ability of a single cell to form a colony. 
HCC cells were seeded into 6-well plates and treated as indicated for 24 h. Subsequently, 
cells were trypsinized and reseeded in fresh medium with 10,000 cells per well in 6-well 
plates. Upon an incubation period of 7 d, cells were stained with crystal violet solution 
(Table 9) for 10 min at room temperature. After washing with distilled water, the bound 
dye was solubilized by adding 1 ml dissolving buffer (Table 9). The absorbance was 
measured at 550 nm in a plate-reading photometer. 
 
2.13 Motility assays 
2.13.1 Boyden Chamber assay 
Transwell® permeable supports (8 µm pore polycarbonate inserts) were used according to 
the manufacturer’s instructions. The transwell inserts were coated with collagen G to 
measure the migration and with Matrigel® to measure the invasion of tumor cells. Inserts 
were added to 24-wells containing 700 µL DMEM (negative control) or DMEM containing 
10% FCS. 100,000 cells in DMEM or DMEM containing indicated agents were added to 
the inside compartments and allowed to migrate for 16 h. Afterwards cells on both sides of 
the insert were stained by crystal violet. Cells on the upper side were removed by using 
cotton swabs and cells attached to the bottom were photographed using a Zeiss Axiovert 
25 microscope and a Canon 450D camera. Eight pictures for each sample were taken and 
the number of cells was counted. 
 
2.13.2 Wound healing assay 
In the wound healing assay, also called scratch assay, a confluent cell monolayer is 
wounded and the ability of the cells to migrate and close the artificial scratch is 
determined. HCC cells were seeded in 24-well plates. After reaching confluence, cells 
were scratched using a pipette tip of a micropipette. The wounded monolayers were 
washed twice with PBS to remove floating cellular debris before adding fresh medium or 
medium containing roscovitine. After about 24 h of migration, cells were washed with PBS 
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and fixed with 4% formaldehyde. As a negative control cells were fixed directly after 
scratching. Images of the fixed cells were taken using an imaging system (TILL Photonics 
GmbH, Gräfelfing, Germany) and a CCD
micro
Germany). Migration was quantified as the ratio of the number of pixels in the area 
covered with cells 
 
Figure 4
with growth medium (left panel) or fixed HUH7 cells directly after scratching (right panel). 
 
2.14
Cell cycle analysis and quantification of apoptosis rate was performed ac
Nicoletti 
If specified, cells were synchronized by treatment with 10 µM aphidicolin for about 24 h 
before measuring the cell cycle. Cells were treated as indicated for
afterwards trypsinized, washed with PBS, and centrifugated at 600 g and 4°C for 10 min. 
For permeabilization and staining, cells were incubated in fluorochrome solution 
buffer
incubation overnight at 4°C
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The respective fluorescence intensity gives information about the DNA content of a cell, 
and thus, about rate of apoptosis and cell cycle phases. Apoptotic cells are characterized 
by DNA fragmentation, indicated by a 
phase) and interphase. The interphase is subdivided into G1/G0
phase, characterized by their DNA contents. The respective fluorescence intensities of 
cell populations result in characteristic histogram plots
 
Figure 5
Distribution of cells in distinct cell cycle phases and percentage of apoptotic cells were 
determined using FlowJo
 
2.15
All experiments were performed according to German legislation for the protection of 
animals and approved by the local government authorities.
perform
 
2.15.1
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2.15.2 Tumor cell implantation 
Normal HUH7 cells or HUH7 cells with Cdk5 knockdown were harvested at about 70% 
confluency and 3.3*106 cells in 100 µl PBS were injected subcutaneously into the flank of 
SCID mice. The number of animals per group is indicated in the corresponding figure 
legend. 
Animals were checked regularly for tumor progression. Tumor volume was determined 
using a digital measuring slide (Digi-Met, Preisser, Gammertingen, Germany). Each 
measurement consisted of three parameters, length (a), width (b) and height (c) and 
tumor volume was calculated by the formula a*b*c*π/6 (with a, b and c indicating the three 
parameters and π/6 as correction factor for tumor shape). 
 
2.15.3 Intraperitoneal application of roscovitine and irinotecan 
Roscovitine and irinotecan were injected intraperitoneally (100 µL; solvent: 
PBS/DMSO/Solutol 17:1:2). For roscovitine treatment alone, application was carried out 
every day with 150 mg/kg (body weight)/d for seven days, beginning seven days after 
implantation. In the combinatorial treatment, the injections began ten days after 
implantation with 150 mg/kg/d roscovitine injected 3-times and 10 mg/kg/d irinotecan 2-
times per week for 4 weeks. 
 
2.15.4 Isolation of tumors 
For investigation of tumor size mice were sacrificed by neck fracture. Tumors were 
removed and weight and volume was determined. Afterwards tumors were fixed with 4% 
paraformaldehyde in PBS for one day and with 1% paraformaldehyde for additional three 
days prior to embedding in paraffin. 
 
2.16 Statistical analysis 
All experiments were performed at least three times unless otherwise indicated in the 
figure legend. Data are expressed as mean ± SEM. Statistical analysis was performed 
with SigmaPlot® software version 10.0 (Systat Software Inc., Chicago, USA). Statistical 
tests are indicated in the figure legend. Statistical significance was considered if p<0.05. 
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3 RESULTS 
3.1 Cdk5 expression is increased in human HCC 
Analysis of Cdk5 in a human HCC tissue microarray46 (Figure 6A) was performed in 
cooperation with Prof. Dr. med. Thomas Kirchner and Prof. Dr. med. Doris Mayr from the 
Institute of pathology and Dr. med. Enrico de Toni from the Department of Internal 
Medicine II of the University of Munich. The evaluation of the microarray revealed an 
increased expression of Cdk5 in human HCC (41.3% with high Cdk5 expression; n=179) 
in comparison to corresponding normal liver tissue (26.4% with high Cdk5 expression; 
n=174). This was confirmed by immunoblots of HCC and corresponding normal liver 
patient samples, where expression of Cdk5 and its activator p35, was increased in HCC 
(Figure 6B). In line, the HCC cell lines HepG2 and HUH7, which were used for further 
studies, showed expression of Cdk5 and p35 (Figure 6C) and Cdk5 activity (Figure 6D). 
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3.2.2
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3.3.3 Cdk5 gets activated by DNA damage and is involved in DNA damage 
response 
Our data demonstrated a role of Cdk5 in the nucleus during G2/M phase. During this 
phase DNA damage response and repair mechanism take place, which are especially 
important for highly proliferating cells as HCC cells. We started out to investigate whether 
Cdk5 affects the response of HCC cells to DNA damage inducing agents and the other 
way around, if DNA damaging agents affect Cdk5. With respect to the latter, we used 
Sn38, an active metabolite of the topoisomerase inhibitor irinotecan, as well as ABT-888, 
an inhibitor of PARP as DNA damage inducing chemotherapeutics. Both drugs led to an 
increase of phosphorylated Cdk5 (Figure 14A) and enhanced Cdk5 activity in the nucleus 
(Figure 14B). Importantly, cells which do not express Cdk5 responded with increased 
amount of DSB indicated by p-H2A.X upon Sn38 exposure in comparison to control cells 
(Figure 14C, D). To examine whether this increase is due to an enhanced induction or 
persistence of DSBs, we analyzed the p-H2A.X after removal of the DNA damage agent. 
Increased DSBs in Cdk5 silenced cells which occur directly after stimulation with Sn38 
does not persist after removal of the DNA damaging agent (Figure 14E). Thus Cdk5 
seems to be involved in the induction of DSBs rather than their persistence.  
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3.3.4 Cdk5 influences DNA damage checkpoint regulation 
The next question was how Cdk5 knockdown causes enhanced DNA damage in HCC 
cells. The topoisomerase I inhibitor Sn38 causes a cell cycle arrest in the G2/M phase in 
control HUH7 cells (Figure 15A). Interestingly, Cdk5 shRNA cells display an increased 
number of cells in the G0/G1 phase upon Sn38 treatment. This effect is not restricted to 
Sn38 as induction of DNA damage by the PARP inhibitor ABT-888 showed the same 
result (Figure 15A). However, if treating the cells with nocodazol, which interferes with 
spindle formation rather than DNA, control as well as Cdk5 knockdown cells arrest equally 
in G2/M phase (Figure 15A). These results together indicate that this overcome of G2/M 
cell cycle arrest occurs only if it is induced by DNA damage. To illustrate whether Cdk5 
knockdown cells arrest already in G0/G1 phase due to DNA damage agents and never 
reach the G2/M phase, or whether they overcome the G2 arrest caused by DNA damage, 
get into G0/G1 phase and accumulate here, we observed the cell cycle at different time 
points during stimulation with Sn38 after synchronizing the cells (Figure 15B). At 8 h to 
12 h after synchronization and Sn38 treatment most of control as well as Cdk5 shRNA 
cells are in G2/M phase. Then the population of cells in G0/G1 phase increased slightly 
during the next 12 h in the control cells, however this population was significantly higher in 
Cdk5 knockdown cells. Obviously Cdk5 is important for activation of the G2/M checkpoint 
and loss of Cdk5 let HCC cells overcome the arrest caused by treatment with DNA 
damage agents. This defect in DNA damage induced checkpoint activation could be the 
cause for the higher amount of DSBs in Cdk5 knockdown cells as Cdk5 knockdown cells 
probably do not stop replicating the DNA.  
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3.3.5 Cdk5 is important for ATM phosphorylation 
In search for the target responsible for Cdk5 induced DNA damage response and 
checkpoint activation the ataxia telangiectasia mutated (ATM) and ataxia telangiectasia 
and Rad3-related (ATR) signaling cascade gained attention. As expected, stimulation of 
HCC cells with Sn38 or ABT-888 led to an increase in ATM phosphorylation due to DNA 
damage. Interestingly, the Cdk5 knockdown cells showed a decreased phosphorylation of 
ATM at Ser1981, which is crucial for its activity (Figure 16A, B). However, there was no 
difference in phosphorylation of ATR due to Cdk5 inhibition and also its downstream 
target the checkpoint kinase (Chk) 1 was unaffected. In contrast, the downstream targets 
of ATM were influenced by Cdk5. Chk2 gets directly phosphorylated by ATM and 
therefore the phosphorylation at Thr68 was reduced in Cdk5 knockdown cells. In addition, 
the breast cancer 1 (BRCA1) protein and cyclin dependent kinase 1 (cdc2) were less 
phosphorylated due to Cdk5 inhibition. Thus ATM is suggested to be an important player 
of Cdk5 in HCC.  
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This combined therapy reduces HCC cell proliferation directly from the beginning of 
treatment. In hospital routines, chemotherapy treatment is given in cycles to attack cancer 
cells most effectively, whereas the body’s normal cells have time to recover in between. 
To get closer to this patient situation, we further tested the combinatorial treatments in 
clonogenic survival assays (Figure 18A). Remarkably, stimulation with all tested DNA 
damage agents and Cdk5 downregulation decrease significantly colony formation ability of 
HCC cells. The profound effect is due to the combined effects of decreased proliferation 
and enhanced apoptosis in Cdk5 knockdown cells 7 days after short-term stimulation 
(Figure 18B). Moreover, these in vitro results could be verified in vivo, as the combined 
systemic treatment of the Cdk5 inhibitor roscovitine and irinotecan, the therapeutically 
used prodrug of Sn38, increased inhibition of tumor growth in a HCC xenograft model 
(Figure 18C).  
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4 DISCUSSION 
Prognosis for patients with advanced stage HCC, i.e. when curative surgery is no longer 
feasible, is very poor. Up to now, oral treatment with the multi tyrosine kinase inhibitor 
sorafenib represents the only approved systemic therapeutic option for advanced stage 
HCC.6 However, its therapeutic success is limited, because response remains low and the 
median overall survival is only extended by 2-3 months.7 This urgently demands for new 
systemic treatment strategies for HCC therapy.  
 
4.1 Cdk5 is an important mediator in HCC progression 
Our present study provides evidence for Cdk5 as a novel target for HCC therapy. In fact, 
we demonstrate for the first time a crucial role of Cdk5 in HCC progression and thereby 
extend the rare knowledge of Cdk5 in cancer. Increased expression of Cdk5 and p35 in 
HCC tissue in comparison to healthy liver tissue goes along with pancreatic cancer49 and 
non-small cell lung cancer, where high expression of Cdk5/p35 is related to poor patient 
prognosis.50  
Moreover in our study, we showed that genetic and pharmacologic inhibition of Cdk5 
decreases significantly HCC cell motility and invasion. Remarkably, Cdk5 controls 
proliferation of HCC cells and inhibits tumor growth in vivo. These findings are partly in 
line with the few publications about Cdk5 in other cancer types, but also reveal a specific 
functional profile and signaling of Cdk5 in HCC. In prostate cancer, Cdk5 regulates cell 
motility and metastatic potential,36 but has no influence on tumor growth, whereas in 
pancreatic cancer, similar to HCC, Cdk5 is involved in the whole tumor progression 
including cell proliferation and motility.37 In pancreatic cancer, Cdk5 acts via activation of 
Ral effector pathway which is essential for oncogenic Ras signaling.37 Furthermore, 
dysregulated high activity of Cdk5 in C cells of the thyroid gland was reported to initiate 
the formation of medullary thyroid carcinoma via phosphorylation of retinoblastoma 
protein.34 Regarding the fact that Cdk5 affects cancer genesis as shown in 
neuroendocrine thyroid cancer it might be reasonable to study the role of Cdk5 in HCC 
onset mostly driven by liver cirrhosis and hepatitis infection in future projects. 
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4.2 Cdk5 regulates DNA damage response and checkpoint 
activation via ATM pathway 
Our results imply a Cdk5 driven signaling which is so far unique and novel in HCC. We 
suggest ATM signaling as Cdk5 downstream pathway responsible for its synergistic 
effects with DNA damage agents in HCC. 
The ATM and ATR signaling cascade is the major response to DNA damage and acts 
thereby on different axes: it regulates cell cycle arrest, activates DNA repair mechanisms, 
and induces cell death.51 ATM acts as sensor for the DNA damage and as transducer for 
the response. In the role of the latter, ATM activates several proteins, like BRCA1, which 
is involved in DNA damage repair,52 the checkpoint kinase 2 (Chk2) and p53. P53 can be 
directly phosphorylated by ATM or indirect via Chk2. The activated p53, in turn, can 
trigger cells to apoptosis or to cell cycle arrest in the G1 phase.51 ATR is another protein 
with a role as transducer in response to DNA damage. As ATR shares high sequence 
homology to ATM, there is a high degree of redundancy in the DNA damage response 
pathways. However, in general, Chk1 is preferentially phosphorylated by ATR, while Chk2 
is the favored ATM substrate.53 Different isoforms of the Cdc25 phosphatase are the 
important key targets of Chk1 and Chk2. Cdc25A regulates progression through S phase, 
and Cdc25B and Cdc25C control mitotic entry.54 The phosphorylation by Chk1 and Chk2 
causes an inactivation of Cdc25 phosphatase. Thus, the ATR/ATM-Chk1/Chk2-Cdc25 
pathways regulate the G1/S and G2/M checkpoints, respectively (Figure 21).  
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of cell cycle, if located in the nucleus,48 whereas in HCC we showed that only cells with 
Cdk5 located in the nucleus are positive for the proliferation marker Ki-67. Along this line, 
one could suggest that function and regulation of Cdk5 in HCC are in parallel to 
neurons, i.e. ATM might be a direct target, but this cannot be transferred without further 
evaluation. 
In addition, we showed that Cdk5 inhibition enhances the response of HCC cells to 
different DNA damaging agents, including topoisomerase inhibitors irinotecan, etoposid 
and doxorubicin, and the PARP inhibitor ABT-888. Our data are in line with studies in 
other cancer types, where an involvement of Cdk5 in DNA damage response has been 
shown.58, 59 However, up to now the ATM signaling is not well investigated in HCC. Thus, 
our results represent an important step in introducing Cdk5 and the ATM pathway as 
possible target for HCC therapy.  
 
4.3 Combination of Cdk5 inhibition with DNA damage agents 
presents a novel therapeutic option for HCC 
Our clinical most important finding showed that combination of Cdk5 inhibition with 
different DNA damage inducing chemotherapeutics synergistically inhibits HCC tumor 
progression by decreasing cell growth and inducing cell death. These results suggested 
novel and promising therapeutic strategies for therapy of patients with advanced stage 
HCC. We tested different DNA damage agents, like irinotecan, ABT-888, etoposid and 
doxorubicin, for the combined treatment with Cdk5 inhibition. 
The PARP inhibitor ABT-888 is up to now mostly studied in preclinical models of different 
cancer types, like glioblastoma, colorectal cancer and prostate cancer.60-62 Some 
publications show also a synergistic effect of ABT-888 with DNA damage induction by 
chemotherapeutics or radiation.63, 64 Our study indicates a benefit of combining this PARP 
inhibitor with Cdk5 inhibition. A combination of Cdk5 inhibition with PARP inhibition and 
DNA damage induction for treatment of HCC patients could represent an additional 
option. 
Doxorubicin is given for treatment of HCC mostly via TACE.65 In some case reports 
doxorubicin is also applied systemically, but the response rate is only 2-10%.66, 67 The 
combination of doxorubicin with cisplatin, interferon and fluorouracil enhances the 
response rate to 20%. However, this is associated with significant toxicity including two 
treatment related deaths.68  
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Irinotecan is well-established as single as well as combination approaches in treatment of 
other cancer types like e.g. metastatic colorectal cancer.69 Importantly, few single case 
reports show a response of HCC patients to irinotecan.70-72 Although potentially effective, 
high dose chemotherapy with irinotecan leads to gastrointestinal and vascular side 
effects, which clearly limits the therapeutic success.73  
Of note, by combining the DNA damage inducing chemotherapeutics with Cdk5 inhibitors, 
as proposed here, the dose can be reduced. This might diminish the problem of high 
toxicity due to the DNA damage agents, as Cdk5 inhibition appears to be well tolerated 
without the typical side effects associated with chemotherapy.74 
In summary we introduced these chemotherapeutics in combination with Cdk5 inhibition 
as new therapeutic strategies. 
 
4.4 Cdk5 inhibition increases efficacy and response to 
sorafenib treatment 
Up to now, sorafenib is the standard first-line systemic drug for treatment of advanced 
HCC. However, its therapeutic benefit is limited, because the overall survival is only 
extended by 2-3 months and due to resistance the response remains low.7 In our work, we 
showed that the efficacy of sorafenib treatment can be enhanced by combination with 
Cdk5 inhibition as combined therapy inhibits synergistically HCC tumor growth and 
prevents sorafenib induced HCC cell migration.  
Sorafenib inhibits a variety of different tyrosine kinases including vascular endothelial 
growth factor receptor (VEGFR-) 1, VEGFR-2, VEGFR-3, platelet-derived growth factor 
receptor (PDGFR-) β, RET, c-KIT, FMS-like tyrosine kinase-3, and also the RAF/mitogen-
activated protein kinase (MAPK)/extracellular signaling-regulated kinase (ERK) pathway 
by targeting Raf-1 and B-Raf.75, 76 The phosphatidylinositol 3-kinase (PI3K)/Akt and the 
MAPK signaling pathways are most important for HCC progression. While the MAPK 
pathway is inhibited by sorafenib, it is reported that Akt is activated by sorafenib as a 
compensatory mechanism. In addition, the resistance to sorafenib could be reversed by 
Akt inhibition, suggesting that the Akt pathway is involved in sorafenib resistance.77-79 
Fujimaki et al. suggest that the sorafenib mediated Akt phosphorylation occurs via ATM 
activation.77 As our findings already showed that Cdk5 inhibition prevents ATM and Akt 
phosphorylation, this could be the mechanistical explanation for the synergistic effect of 
4  DISCUSSION 64 
  
 
combining sorafenib with Cdk5 inhibition. This combination is a new therapeutic approach 
to enhance sorafenib treatment response and efficacy. 
 
4.5 Cdk5 represents a novel drugable target for HCC therapy 
One of the earliest and most popular Cdk5 inhibitors is roscovitine. However, it is far from 
selectively inhibiting Cdk5 as it also targets Cdk1, Cdk2, Cdk7, Cdk9, ERK1/2 and 
pyridoxal kinase.39, 40 During last years, many groups tried to develop new Cdk5 inhibitors 
with improved potency and selectivity using roscovitine as mother substance80-82 and also 
other lead structures, e.g. Dinaciclib (SCH 727965).83-85 Most of these compounds show 
an increased potency for Cdk5 inhibition, but they still share the problem of selectivity as 
they target at least also Cdk1 and Cdk2. This selectivity problem occurs due to their 
interaction with the ATP-binding pocket which is quite conserved throughout the Cdk 
family. A new approach is the inhibition of the interaction of Cdk5 and its activators.86, 87 
These inhibitors mainly target the interaction of Cdk5 and p25, the truncated form of p35, 
which is associated with a dysregulated activity of Cdk5 and therefore with pathogenesis 
of neurodegenerative diseases. Zeng et al. reported that a short peptide called CIP (Cdk5 
inhibitory peptide), which is derived from p35, specifically inhibits the Cdk5/p25 activity, 
without affecting the activity of Cdk1 or Cdk5/p35.88, 89 Thus, targeting the interaction of 
Cdk5 and its activators represents a promising option for developing selective Cdk5 
inhibitors. However, to use this approach in HCC, it is important to elucidate first if Cdk5 
activity in HCC depends also on binding to p35 and p25, like in neurons, or on different 
proteins. 
 
4.6 Conclusion and further perspectives 
In conclusion, this study for the first time presents a novel and crucial function of Cdk5 in 
HCC cell motility and tumor growth. We showed that inhibition of Cdk5 potentiates the 
antitumor effects of different DNA damage agents and sorafenib in hepatoma cells and 
suggested a specific signaling pathway for these effects. Our work demonstrate Cdk5 as a 
drugable target in HCC and proposes the combination of DNA damage inducing 
chemotherapeutics or sorafenib and Cdk5 inhibition as a novel and promising therapeutic 
strategy for this almost lethal disease.  
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5 SUMMARY 
For a long time cyclin dependent kinase 5 (Cdk5) was thought to be of exclusive 
importance in neuronal cells. However, recently increasing evidence suggests a function 
of Cdk5 in cancer progression. In the present study, we examined the role of Cdk5 in 
hepatocellular carcinoma (HCC), a highly chemoresistant cancer with poor prognosis. 
Consequently, development of novel targeted therapies for HCC is of paramount clinical 
importance. Analysis of human HCC patient samples showed an increased expression of 
Cdk5 as compared to normal liver tissues. Functional ablation of Cdk5 significantly 
decreases HCC cell proliferation and clonogenic survival, and reduces cell motility and 
invasion. Of note, genetic as well as pharmacologic inhibition of Cdk5 also shows in vivo 
efficacy in a HCC xenograft mouse model. Investigating the mechanism behind these 
functional effects revealed that Cdk5 is most active in the nucleus of cells in G2/M phase. 
In this cell cycle phase DNA damage response takes place, which is affected by Cdk5 
inhibition. Furthermore, Cdk5 leads to phosphorylation of Ataxia Telangiectasia Mutated 
(ATM) and thereby influence its downstream signaling. Importantly, combination of Cdk5 
inhibition with different DNA damage inducing chemotherapeutics or the first-line systemic 
drug sorafenib inhibits synergistically HCC tumor progression.  
 
 
In conclusion, we introduce: 
1. Cdk5 as a novel drugable target for treatment of HCC 
2. The combination of Cdk5 inhibition and DNA damage agents as a novel 
therapeutic approach 
3. An increased efficacy of sorafenib treatment by combing with Cdk5 inhibition 
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7 APPENDIX 
7.1 Abbreviations 
AEC 3-amino-9-ethylcarbazole 
ANOVA Analysis of variance between groups 
APS  ammonium persulfate 
ATM  ataxia telangiectasia mutated 
ATP  adenosine-5’-triphosphate 
ATR  ataxia telangiectasia and Rad3 related 
BRCA1 breast cancer 1 
BSA bovine serum albumin 
c-Abl  c-Abelson 
cdc2 cell division cycle protein 2 
Cdk cyclin dependent kinase 
Chk checkpoint kinase 
CIP Cdk5 inhibitory peptide 
CNS central nervous system 
CREB cyclic adenosine monophosphate response element-binding 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO  dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DSMZ German Research Centre of Biological Material 
DTT dithiothreitol 
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
ERK extracellular signal-regulated kinases 
FACS  fluorescence activated cell sorter 
FCS  fetal calf serum 
FL2-A fluorescent channel 2 area 
FL2-H fluorescent channel 2 height 
FS fluorochrome solution 
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HCC hepatocellular carcinoma 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP  horseradish peroxidase 
JCRB Japanese Collection of Research Bioresources 
MAPK mitogen-activated protein kinase 
min  minute 
MOI  multiplicity of infection 
PBS phosphate buffered saline 
PDGFR platelet derived growth factor receptor 
PI propidium iodide 
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase 
PMSF phenylmethylsulfonyl fluoride 
RFA  radiofrequency ablation 
RNA  ribonucleic acid 
rpm revolutions per minute 
SCID severe combined immunodeficiency 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM standard error of the mean value 
shRNA short hairpin ribonucleic acid 
siRNA small interfering ribonucleic acid 
TACE transarterial chemoembolization 
T/E trypsin/EDTA 
TEMED N, N, N’, N’ tetramethylethylene diamine 
TMA tissue microarray 
Tris trishydroxymethylaminomethane 
TUNEL terminal deoxynucleotidyl transferase mediated deoxyuridine 
triphosphate Nick End Labeling 
Tyr tyrosine 
VEGFR vascular endothelial growth factor receptor 
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